The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

Scientists have uncovered a hidden molecule in DNA that helps control fat storage, offering hope for a new kind of obesity ...

A new report shows childhood obesity rates in Roanoke have fallen since the COVID-19 pandemic. The Roanoke Valley Community ...

Pharmacotherapy is an effective, evidence-based treatment for people living with obesity, as part of a long-term, ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

In a study conducted at the University of Hawaiʻi at Mānoa, researchers from the John A. Burns School of Medicine (JABSOM) ...

Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...

High-fat diets and obesity reshape astrocytes—star-shaped brain cells in the striatum that help regulate pleasure from eating ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...